A phase 1 clinical trial of BS-112 tablets in healthy individuals
Latest Information Update: 27 Jan 2023
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Adverse reactions
Most Recent Events
- 27 Jan 2023 New trial record
- 01 Jul 2021 According to a Bio-Synectics media release, based on the results of this clinical trial, Biosynetics plans to develop BS-112 tablets 20mg as an anticoagulant.